From NA /K+-ATPase and cardiac glycosides to cytotoxicity and cancer treatment

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 7, 2013, Pages 1069-1087

  Babula, Petr ^a   Masarik, Michal ^b   Adam, Vojtech ^b   Provaznik, Ivo ^a   Kizek, Rene ^b  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^b MENDEL UNIVERSITY IN BRNO   (Czech Republic)

Author keywords

Apoptosis; Cancer; Cardiac glycosides; Cytostatics; Fxyd proteins; Na+ k+ atpase

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BUFADIENOLIDE; BUFALIN; CARDENOLIDE; CARDIAC GLYCOSIDE; CINOBUFAGIN; DIGITOXIN; DIGOXIN; ERLOTINIB; EXCITATORY AMINO ACID TRANSPORTER 1; FXYD 1; FXYD 2; FXYD 3; FXYD 4; FXYD 6; FXYD 7; GEMCITABINE; HUACHANSU; LANATOSIDE C; LAPATINIB; NERIIFOLIN; OLEANDRIN; OUABAIN; OXALIPLATIN; PBI 05204; PROSCILLARIDIN; PROTEIN; SORAFENIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNBS1450; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL CYCLE; CELL PROLIFERATION; COLON CANCER; CYTOTOXICITY; FIBROBLAST; HEART FAILURE; HEPATOMA CELL; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; RADIOSENSITIZATION; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIAC GLYCOSIDES; CARDIOTONIC AGENTS; CYTOTOXINS; HEART FAILURE; HUMANS; NEOPLASMS; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84882754000     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113139990304     Document Type: Article

References (330)

1. Yamauchi, T.; Abe, F. Cardiac-Glycosides and Pregnanes from Adenium-Obesum (Studies on the Constituents of Adenium.1.). Chem. Pharm. Bull., 1990, 38(3), 669-672.
2. Abe, F.; Yamauchi, T. Studies on Cerbera.1. Cardiac-Glycosides in Seeds, Bark, and Leaves of Cerbera-Manghas L. Chem. Pharm. Bull., 1977, 25(10), 2744-2748.
3. Kamel, M. S.; Assaf, M. H.; Abe, Y.; Ohtani, K.; Kasai, R.; Yamasaki, K. Cardiac glycosides from Cryptostegia grandiflora. Phytochemistry 2001, 58(4), 537-542.
4. Yamauchi, T.; Takahashi, M.; Abe, F. Nerium.6. Cardiac-Glycosides of Root Bark of Nerium-Odorum. Phytochemistry 1976, 15(8), 1275-1278.
5. Yamauchi, T.; Takata, N.; Mimura, T. Nerium.5. Cardiac-Glycosides of Leaves of Nerium-Odorum. Phytochemistry 1975, 14(5-6), 1379-1382.
6. Cao, J. X.; Wang, Y. F.; Lai, G. F.; De Luo, S. A novel cardiac glycoside from Parepigynum funingesis. Chin. Chem. Lett. 2004, 15(7), 797-800.
7. Cao, J. X.; Luo, S. D. Two novel types of cardiac glycosides from Parepigynum funingense and the possible biogenesis. Chin. J. Chem. 2005, 23(7), 905-912.
8. Zhang, Y. H.; Chen, D. L.; Wang, F. P. Two novel cardiac glycosides from Periploca forrestii. Chin. J. Org. Chem. 2006, 26(3), 329-332.
9. Spera, D.; Siciliano, T.; De Tommasi, N.; Braca, A.; Vessieres, A. Antiproliferative cardenolides from Periploca graeca. Planta Med. 2007, 73(4), 384-387.
10. Li, Y.; Wu, X. F.; Li, J. B.; Wang, Y. H.; Yu, S. S.; Lv, H. N.; Qu, J.; Abliz, Z.; Liu, J.; Liu, Y. Y.; Du, D. Identification of cardiac glycosides in fractions from Periploca forrestii by high-performance liquid chromatography/diode-array detection/ electrospray ionization multi-stage tandem mass spectrometry and liquid chromatography/nuclear magnetic resonance. J. Chromatogr. B, 2010, 878(3-4), 381-390.
11. Bush, I. E.; Taylor, D. A. H. The Paper-Chromatographic Examination of the Cardiac Aglycones of Strophanthus Seeds. Biochem. J., 1952, 52(5), 643-648.
12. Heftmann, E.; Berner, P.; Hayden, A. L.; Miller, H. K.; Mosettig, E. Identification of Cardiac Glycosides and Aglycones in Strophanthus Seeds by Paper Chromatography. Arch. Biochem. Biophys., 1954, 51(2), 329-339.
13. Davies, M. K.; Hollman, A. Digitalis and strophanthus-cardiac glycosides. Heart, 1998, 80(1), 4-4.
14. Hostettmann, K.; Marston, A.; Ndjoko, K.; Wolfender, J. L. The potential of African plants as a source of drugs. Curr. Org. Chem., 2000, 4(10), 973-1010.
15. Makarevich, I. F.; Kovalev, S. V. Cardiac glycosides from Strophanthus kombe. Chem. Nat. Compd., 2006, 42(2), 189-193.
16. Chen, K. K.; Chen, A. L. The action of crystalline thevetin, a cardiac glucoside of Thevetia neriifolia. J. Pharmacol. Exp. Ther., 1934, 51(1), 23-34.
17. Mendez, R. Tevetoidin, a Cardiac Glycoside from a Mexican Species of Thevetia. J. Pharmacol. Exp. Ther., 1951, 101(1), 27-27.
18. Jolad, S. D.; Hoffmann, J. J.; Cole, J. R.; Tempesta, M. S.; Bates, R. B. 3'-O-Methylevomonoside-a New Cyto-Toxic Cardiac Glycoside from Thevetia-Ahouia a Dc (Apocynaceae). J. Org. Chem., 1981, 46(9), 1946-1947.
19. Kyerematen, G.; Hagos, M.; Weeratunga, G.; Sandberg, F. The Cardiac-Glycosides of Thevetia-Ovata a Dc and Thevetia-Nereifolia Juss Ex Stend. Acta Pharmaceut. Suec., 1985, 22(1), 37-44.
20. Abe, F.; Yamauchi, T.; Wan, A. S. C. Cardiac-Glycosides from the Leaves of Thevetia-Neriifolia. Phytochemistry, 1992, 31(9), 3189-3193.
21. Siddiqui, S.; Siddiqui, B. S.; Adil, Q.; Begum, S. Cardenolides and Triterpenoids of the Leaves of Thevetia-Neriifolia. Phytochemistry, 1992, 31(10), 3541-3546.
22. Endo, H.; Warashina, T.; Noro, T.; Castro, V. H.; Mora, G. A.; Poveda, L. J.; Sanchez, P. E. Cardenolide glycosides from Thevetia ahouai (Linn.) A.DC. Chem. Pharm. Bull., 1997, 45(9), 1536-1538.
23. Makarevich, I. F.; Pavlii, A. I.; Makarevich, S. I. Cardiac-Glycosides of Cheiranthus-Allioni.13. Glycoericordin. Khimiya Prir. Soedin., 1989, 1989(1), 73-75.
24. Makarevich, I. F.; Zhernoklev, K. V.; Slyusarskaya, T. V.; Magomedova, A. O.; Terekhova, T. N.; Sirenko, G. T. Cardiac-Glycosides of Erysimum-Contractum. Khimiya Prir. Soedin., 1991, 1991(1), 58-62.
25. Makarevich, I. F.; Zhernoklev, K. V.; Slyusarskaya, T. V.; Yarmolenko, G. N. Cardiac-Glycosides of Erysimum-Contractum.3. Glucocanesceine. Khimiya Prir. Soedin., 1993, 1993(5), 766-767.
26. Lei, Z. H.; Jin, Z. X.; Ma, Y. L.; Tai, B. S.; Kong, Q.; Yahara, S.; Nohara, T. Cardiac glycosides from Erysimum cheiranthoides. Phytochemistry, 1998, 49(6), 1801-1803.
27. Makarevich, I. F.; Kovalev, S. V.; Slyusarskaya, T.V.; Zhernoklev, K. V. Cardiac glycosides of Erysimum leptophyllum. Chem. Nat. Compd. 1999, 35(4), 473-474.
28. Lei, Z. H.; Yahara, S.; Nohara, T.; Tai, B. S.; Xiong, J. Z.; Ma, Y.L. Cardiac glycosides from Erysimum cheiranthoides. Chem. Pharm. Bull., 2000, 48(2), 290-292.
29. Lei, Z. H.; Nakayama, H.; Kuniyasu, A.; Tai, B. S.; Nohara, T. Cardiac glycosides from Erysimum cheiranthoides. Chem. Pharm. Bull., 2002, 50(6), 861-862.
30. Hyun, J. W.; Shin, J. E.; Lim, K. H.; Sung, M. S.; Park, J. W.; Yu, J. H.; Kim, B. K.; Paik, W. H.; Kang, S. S.; Park, J. G. Evomonoside-the Cytotoxic Cardiac Glycoside from Lepidium-Apetalum. Planta Med., 1995, 61(3), 294-295.
31. Bliss, C. A.; Ramstad, E. Cardiac Glycosides of Euonymus-Atropurpurea Jacq.1. Detection, Separation, and Isolation. J. Am. Pharm. Assoc., 1957, 46(1), 15-18.
32. Bliss, C. A.; Ramstad, E. Cardiac Glycosides of Euonymus Atropurpurea Jacq.2. A Study of the Structure of Euatroside and Euatromonoside. J. Am. Pharm. Assoc., 1957, 46(7), 423-426.
33. Wagner, H.; Habermeier, H.; Liptak, A.; Schulten, H. R. Chemistry of Cytotoxic Arrow Poison of Lophopetalum-Toxicum.1. Studies on Cardiac-Glycosides Using Field Desorption Mass-Spectrometry. Planta Med., 1979, 37(4), 381-387.
34. Karrer, W. The presentation of a crystallised cardiac glucoside from Convallaria majalis L. Helv. Chim. Acta, 1929, 12, 506-511.
35. Erbring, H.; Patt, P. Glycosides with Native Cardiac Action Contained in Convallaria-Majalis-Zur Chemie. Arzneimittelforschung, 1958, 8(8), 554-557.
36. Lorenz, D.; Stoeckert, I. Native Glycosides of Convallaria-Majalis with Cardiac Action.2. Zur Pharmakologie. Arzneimittelforschung, 1958, 8(8), 557-564.
37. Lipkovskii, A. S. Research in Production of Cardiac-Glycosides.4. Study of Process of Convallaria Majalis Grass Extraction. Khim.-Farm. Zhurnal, 1976, 10(2), 101-103.
38. Loffelhardt, W.; Kopp, B.; Kubelka, W. Cardiac Glycoside Interconversions at Subcellular Level in Convallaria-Majailis. Phytochemistry, 1978, 17(9), 1581-1584.
39. Loffelhardt, W.; Kopp, B.; Kubelka, W. Intracellular-Distribution of Cardiac-Glycosides in Leaves of Convallaria-Majalis. Phytochemistry, 1979, 18(8), 1289-1291.
40. Jurenitsch, J.; Kopp, B.; Kirchner, H.; Kubelka, W. Determination of Cardiac-Glycosides in Convallaria-Majalis and Urginea-Maritima by Reversed Phase Hplc. Planta Med., 1980, 39(3), 272-273.
41. Kopp, B.; Loffelhardt, W.; Kubelka, W. The Glucosylation of Cardiac-Glycosides in Leaves of Convallaria-Majalis L. Planta Med., 1980, 39(3), 289-290.
42. Schenk, B.; Junior, P.; Wichtl, M. Cannogenol-3-0-Alpha-LRhamnoside and Cannogenol-3-0-Beta-D-Allomethyloside, 2 New Cardiac-Glycosides from Convallaria-Majalis. Planta Med., 1980, 40(1), 1-11.
43. Jurenitsch, J.; Kopp, B.; Bambergkubelka, E.; Kern, R.; Kubelka, W. High-Performance Liquid-Chromatographic Separation of the Cardiac-Glycosides of Convallaria-Majalis L by Coupling Reversed-Phase Columns of Different Polarity. J. Chromatogr., 1982, 240(1), 125-135.
44. Schrutkarechtenstamm, R.; Kopp, B.; Loffelhardt, W. Bioconversions Leading to Minor Cardiac-Glycosides in Convallaria-Majalis. Phytochemistry, 1986, 25(5), 1107-1109.
45. Krenn, L.; Schlifelner, L.; Stimpfl, T.; Kopp, B. A new HPLC method for the quantification of cardenolides in Convallaria majalis L. Pharmazie 1996, 51(11), 906-909.
46. Planellas, M.; Torrente, C.; Roura, X.; Pastor, J. Canine poisoning with cardiac glycosides due to the ingestion of Cotyledon orbiculata. Clin. Vet. Pequenos Anim., 2010, 30(1), 31-34.
47. Vanrooyen, J. M.; Vanderwalt, J. J. The Toxic Effects on Cardiac Myocytes of Tyledoside-F, a Cumulative Neurotoxic Cardiac Glycoside Isolated from Tylecodon-Grandiflorus. Onderstepoort J. Vet. Res., 1990, 57(4), 223-227.
48. Botha, C. J.; Van der Lugt, J. J.; Erasmus, G. L.; Kellerman, T. S.; Schultz, R. A.; Vleggaar, R. Krimpsiekte, associated with thalamic lesions, induced by the neurotoxic cardiac glycoside, cotyledoside, isolated from Tylecodon wallichii (Harv.) Toelken subsp. wallichii. Onderstepoort J. Vet. Res., 1997, 64(3), 189-194.
49. Jager, A. K.; Vanstaden, J. Screening for Cardiac-Glycosides in Schizobasis-Intricata. South Afr. J. Bot.-Suid-Afr. Tydskr. Plantkunde, 1995, 61(2), 101-103.
50. Krenn, L.; Ferth, R.; Robien, W.; Kopp, B. Bufadienolide Aus Urginea-Maritima-Sensu-Strictu-Bufadienolides from Urginea-Maritima-Sensu-Strictu. Planta Med., 1991, 57(6), 560-565.
51. Louw, P. G. J. 2 New Cardiac Glycosides, Rubellin and Transvaalin, from South African Species of Urginea. Nature, 1949, 163(4131), 30-31.
52. Komissarenko, A. N. Cardenolides of Coronilla glauca and Cscorpioides seeds-New glycosides of alloglaucoside and scorpiosidole. Khimiya Prir. Soedin., 1996, 1996(3), 372-376.
53. Komissarenko, A. N.; Kovalev, V. N. Coronillobiosydol, Cardenolide Glycoside of Coronilla-Scorpioides Seeds. Khimiya Prir. Soedin., 1988, 1988(5), 726-728.
54. Mahato, S. B.; Sahu, N. P.; Roy, S. K.; Pramanik, B. N. Cardiac-Glycosides from Corchorus-Olitorius. J. Chem. Soc.-Perkin Trans., 1989, 1989(11), 2065-2068.
55. Kondo, K.; Akiyama, H.; Goda, Y.; Toyoda, M. Determination of cardiac glycosides in Moroheiya (Corchorus olitorius) and its products by HPLC. J. Food Hyg. Soc. Jpn., 1997, 38(6), 412-417.
56. Goda, Y.; Sakai, S.; Nakamura, T.; Akiyama, H.; Toyoda, M. Identification and analyses of main cardiac glycosides in Corchorus olitorius seeds and their acute oral toxicity to mice. J. Food Hyg. Soc. Jpn., 1998, 39(4), 256-265.
57. Allgeier, H.; Weiss, E.; Reichste T. Die Cardenolide Der Samen Von Mansonia Altissima a Chev. Helv. Chim. Acta, 1967, 50(2), 431-455.
58. Allgeier, H.; Weiss, E.; Reichste T. Die Cardenolide Der Samen Von Mansonia Altissima a Chev-Die Struktur Von Mansonin Und Strophothevosid. Helv. Chim. Acta, 1967, 50(2), 456-462.
59. Carter, C. A.; Forney, R. W.; Gray, E. A.; Gehring, A. M.; Schneider, T. L.; Young, D. B.; Lovett, C. M.; Scott, L.; Messer, A. C.; Richardson, D. P. Toxicarioside A. A new cardenolide isolated from Antiaris toxicaria latex-derived dart poison. Assignment of the H-1-and C-13-NMR shifts for an antiarigenin aglycone. Tetrahedron, 1997, 53(40), 13557-13566.
60. Carter, C. A.; Gray, E. A.; Schneider, T. L.; Lovett, C. M.; Scott, L.; Messer, A. C.; Richardson, D. P. Toxicarioside B and toxicarioside C. New cardenolides isolated from Antiaris toxicaria latex-derived dart poison. Tetrahedron, 1997, 53(50), 16959-16968.
61. Dai, H. F.; Gan, Y. J.; Que, D. M.; Wu, J.; Wen, Z. C.; Mei, W. L. Two new cytotoxic cardenolides from the latex of Antiaris toxicaria. J. Asian Nat. Prod. Res. 2009, 11(9), 832-837.
62. Brauchli, P.; Reichstein, T.; Schindler, O. The Cardenolide Content of Castilla-Elastica-Cerv. Helv. Chim. Acta, 1961, 44(4), 904-909.
63. Rovinski, J. M.; Tewalt, G. L.; Sneden, A. T. Maquiroside a, a New Cytotoxic Cardiac Glycoside from Maquira-Calophylla. J. Nat. Prod., 1987, 50(2), 211-216.
64. Decarvalho, J. E.; Torres, L. M. B.; Lapa, A. J. Cardiac-Glycosides Isolated from the Indian-Snuff, Maquira-Sclerophylla Ducke. Mem. Inst. Oswaldo Cruz., 1991, 86(235-236.
65. Shrestha, T.; Kopp, B.; Bisset, N. G. The Moraceae-Based Dart Poisons of South-America-Cardiac-Glycosides of Maquira and Naucleopsis Species. J. Ethnopharmacol., 1992, 37(2), 129-143.
66. deCarvalho, J. E.; Souccar, C.; Tersariol, I. L.; Torres, L. B.; Lapa, A. J. Pharmacological properties and identification of cardiotonic principles from the Indian snuff, Maquira sclerophylla, Ducke. Phytother. Res., 1997, 11(2), 136-141.
67. Sandberg, F.; Thorsen, R. Phytochemical and Pharmacological Investigations of Water-Soluble Cardiac Glycosides of Adonis Vernalis. Lloydia, 1962, 25(3), 201.
68. Elkiey, M. A.; Sayed, M. D.; Wahab, S. M. A.; Soliman, F. M. Estimation of Cardiac Glycosidal-Contents of Adonis Autumnalis Linn and Adonis Dentata Del. Planta Med., 1967, 15(2), 201-204.
69. Mathe, A.; Mathe, I. Data to the Cardiac Glycoside Content of Adonis-Vernalis L, in Hungary. Planta Med., 1979, 36(3), 234-235.
70. Shoushan, A.; Abdalla, N. M.; Elgengaihi, S. E.; Elbadway, A. A. Growth and Cardiac-Glycosides Content of Adonis-Autumnalis L as Affected by the Growth-Retardants Ethrel and Cycocel. Gartenbauwissenschaft, 1981, 46(3), 101-105.
71. Kopp, B.; Krenn, L.; Kubelka, E.; Kubelka, W. Cardenolides from Adonis-Aestivalis. Phytochemistry, 1992, 31(9), 3195-3198.
72. Grunwald, D.; Lutkefels, E.; Wohlsein, P. Intoxication of a dog with winter aconite (Eranthis hyemalis). Kleintierpraxis, 2002, 47(10), 587.
73. Chen, K. K.; Henderson, F. G.; Anderson, R. C. The Cardiac Action of Helleborus Glycosides and Their Aglycones. J. Pharmacol. Exp. Ther., 1950, 99(4), 395-400.
74. Okada, M.; Yamada, A.; Kometani, K. Paper Chromatography of Cardiac Glycosides and Aglycones of Digitalis Leaves. Yakugaku Zasshi-J. Pharm. Soc. Jpn., 1952, 72(7), 930-932.
75. Stoll, A. The Cardiac Glycosides of Digitalis. Chem. Ind., 1959, 1959(50), 1558-1567.
76. Calcandi, V.; Calcandi, I.; Lungeanu, I. Cardiac Glycosides of Digitalis Ciliata Trautv and Digitalis Mertonensis Buxt Et Darl Leaves. Pharmazie, 1968, 23(6), 343.
77. Calcandi, V.; Calcandi, I.; Lungeanu, I. Cardiac Glycosides of Leaves Form Digitalis-Cariensis Ssp Trojana. Pharmazie, 1971, 26(3), 182.
78. Menon, I. S. Digitalis and Cardiac Glycosides. Clinician, 1973, 37(10), 392-394.
79. Lugt, C. B.; Noordhoe L. Quantitative Fluorimetric Determination of Main Cardiac-Glycosides in Digitalis-Purpurea Leaves. Planta Med., 1974, 25(3), 267-273.
80. Imre, Z.; Ersoy, O. Cardiac Glycosides from Leaves of Digitalis Schischkinii (Ivan) Werner. Arch. Pharm., 1977, 310(2), 142-151.
81. Gwasawa, Z. N.; Kemerrelidse, E. P. Some Cardiac-Glycosides from the Leaves Digitalis-Ciliata. Khimiya Prir. Soedin., 1980, 1980(6), 849-849.
82. Imre, Z.; Ersoy, O.; Yurdun, T. Cardiac Glycoside Composition in the Leaves of Digitalis-Schischkinii. Planta Med., 1982, 45(4), 203-206.
83. Kruger, D.; Junior, P.; Wichtl, M. New Cardiac-Glycosides from Digitalis-Lanata. Planta Med., 1983, 49(2), 74-78.
84. Kruger, D.; Wichtl, M. New Cardiac-Glycosides from Digitalis-Lanata. Planta Med., 1984, 50(3), 265-267.
85. Kruger, D.; Wichtl, M. New Cardiac-Glycosides from Digitalis-Lanata. Planta Med., 1984, 50(3), 267-269.
86. Somberg, J. C.; Miura, D. S.; Levitt, B. Digitalis-an Update on Cardiac-Glycosides. Hosp. Formul., 1985, 20(2), 211.
87. Woodcock, B. G.; Rietbrock, N. The forgotten cardiac glycoside of digitalis-purpurea. Trends Pharmacol. Sci., 1985, 6(7), 273-275.
88. Imre, Z.; Yurdun, T. Cardiac-glycosides from the leaves of digitalis-cariensis. Planta Med., 1987, 53(1), 43-46.
89. Imre, Z.; Yurdun, T. Cardiac-glycosides from the seeds of digitaliscariensis. Planta Med., 1988, 54(6), 529-531.
90. Hoelz, H.; Kreis, W.; Haug, B.; Reinhard, E. Storage of Cardiac-Glycosides in Vacuoles of Digitalis-Lanata Mesophyll-Cells. Phytochemistry, 1992, 31(4), 1167-1171.
91. Stuhlemmer, U.; Kreis, W.; Eisenbeiss, M.; Reinhard, E. Cardiac-Glycosides in Partly Submerged Shoots of Digitalis-Lanata. Planta Med., 1993, 59(6), 539-545.
92. Gil, R. R.; Lin, L. Z.; Chai, H. B.; Pezzuto, J. M.; Cordell, G. A. Cardenolides from Nierembergia-Aristata. J. Nat. Prod., 1995, 58(6), 848-856.
93. Schoner, W. Endogenous cardiac glycosides, a new class of steroid hormones. Eur. J. Biochem., 2002, 269(10), 2440-2448.
94. Hamlyn, J. M. Biosynthesis of endogenous cardiac glycosides by mammalian adrenocortical cells: Three steps forward. Clin. Chem., 2004, 50(3), 469-470.
95. Heasley, B. Chemical Synthesis of the Cardiotonic Steroid Glycosides and Related Natural Products. Chem.-Eur. J., 2012, 18(11), 3092-3120.
96. Lingrel, J. B.; Arguello, J. M.; Van Huysse, J.; Kuntzweiler, T. A., Cation and cardiac glycoside binding sites of the Na,K-ATPase. In Na/K-Atpase and Related Transport Atpases: Structure, Mechanism, and Regulation, New York Acad Sciences: New York, 1997; pp 194-206.
97. Ruch, S. R.; Nishio, M.; Wasserstrom, J. A. Effect of cardiac glycosides on action potential characteristics and contractility in cat ventricular myocytes: Role of calcium overload. J. Pharmacol. Exp. Ther., 2003, 307(1), 419-428.
98. Paula, S.; Tabet, M. R.; Ball, W. J. Interactions between cardiac glycosides and sodium/potassium-ATPase: Three-dimensional structure-activity relationship models for ligand binding to the E-2-P-i form of the enzyme versus activity inhibition. Biochemistry, 2005, 44(2), 498-510.
99. Lingrel, J. B.; Dostanic, I.; Lorenz, J.; Van Huysse, J. W.; Neumann, J. Significance of the conserved cardiac glycoside binding site of the alpha 2 isoform of the Na,K-ATPase. J. Gen. Physiol., 2005, 126(1), 10A-10A.
100. Ball, W. J.; Tabet, M.; Paula, S. Structure-activity relationship models for cardiac glycoside binding and inhibition of Na,KATPase activity. Febs J., 2005, 272, 186-186.
101. Sagawa, T.; Sagawa, K.; Kelly, J. E.; Wasserstrom, J. A. Effects of cardiac glycosides on canine cardiac SR Ca2+ release channels. Biophys. J., 1999, 76(1), A304-A304.
102. Medarde, M.; Caballero, E.; Tome, F.; San Feliciano, A. Cardenolides and diterpenes as a source of and model for positive ionotropic agents. Pharm. Biol., 2001, 39, 53-62.
103. Liu, T.; Brown, D. A.; O'Rourke, B. Role of mitochondrial dysfunction in cardiac glycoside toxicity. J. Mol. Cell. Cardiol., 2010, 49(5), 728-736.
104. Bohm, M. Current and established aspects of cardiac glycoside therapy for chronic heart failure. Perfusion, 1996, 9(6), 257-257.
105. Kania, B. F. The therapeutic effects of cardiac glycosides. Med. Weter., 2000, 56(12), 772-776.
106. Veloso, H. H. Effects of cardiac glycosides on atrial fibrillation. Chest, 2001, 120(5), 1753-1754.
107. Bohm, M. Do we still need cardiac glycosides? Dtsch. Med. Wochenschr., 2002, 127(41), 2133-2138.
108. Sidorenko, B. A.; Preobrazhensky, D. V.; Sharoshina, I. A.; Batyraliev, T. A.; Pershukov, I. V.; Mahmuthodzhaev, S. A. The place of cardiac glycosides in the treatment of chronic heart failure. Part III. The DIG trial. Kardiologiya, 2005, 45(6), 61-70.
109. Sidorenko, B. A.; Preobrazhensky, D. V.; Sharoshina, I. A.; Batyraliev, T. A.; Pershukov, I. V.; Makhmutkhodzhaev, S. A. The place of cardiac glycosides in the treatment of chronic heart failure. Part II. Results of small studies. Kardiologiya 2005, 45(5), 78-85.
110. Sidorenko, B. A.; Preobrazhensky, D. V.; Sharoshina, I. A.; Makhmutkhodzhaev, S. A.; Batyraliev, T. A.; Pershukov, I. V. The place of cardiac glycosides in the treatment of chronic heart failure. Part 1. Clinical pharmacology. Kardiologiya, 2005, 45(4), 85-91.
111. Schoner, W.; Scheiner-Bobis, G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am. J. Physiol.-Cell Physiol., 2007, 293(2), C509-C536.
112. Sagawa, T.; Sagawa, K.; Kelly, J. E.; Tsushima, R. G.; Wasserstrom, J. A. Activation of cardiac ryanodine receptors by cardiac glycosides. Am. J. Physiol.-Heart Circul. Physiol., 2002, 282(3), H1118-H1126.
113. Ho, H. T.; Stevens, S. C. W.; Terentyeva, R.; Carnes, C. A.; Terentyev, D.; Gyorke, S. Arrhythmogenic adverse effects of cardiac glycosides are mediated by redox modification of ryanodine receptors. J. Physiol.-London, 2011, 589(19), 4697-4708.
114. +-ATPase alpha 1 Subunit of Hepatoma HepG2 Cell Line to Induce Apoptosis and Cell Cycle Arresting. Biol. Pharm. Bull., 2010, 33(5), 743-751.
115. Wang, L.; Dennis, A.; Wan, X. P.; Ficker, E. Cardiac glycosides induce hERG misfolding via changes in intracellular ion composition. Biophys. J., 2007, Suppl. S,121A-121A.
116. Wang, L.; Wible, B. A.; Wan, X. P.; Ficker, E. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J. Pharmacol. Exp. Ther., 2007, 320(2), 525-534.
117. Cirri, E.; Katz, A.; Mishra, N. K.; Belogus, T.; Lifshitz, Y.; Garty, H.; Karlish, S. J. D.; Apell, H. J. Phospholemman (FXYD1) Raises the Affinity of the Human alpha(1)beta(1) Isoform of Na,KATPase for Na Ions. Biochemistry, 2011, 50(18), 3736-3748.
118. Mishra, N. K.; Peleg, Y.; Cirri, E.; Belogus, T.; Lifshitz, Y.; Voelker, D. R.; Apell, H. J.; Garty, H.; Karlish, S. J. D. FXYD Proteins Stabilize Na,K-ATPase Amplification of specific phosphatidylserine-protein interactions. J. Biol. Chem., 2011, 286(11), 9699-9712.
119. Kasturi, S.; Ismail-Beigi, F. Effect of thyroid hormone on the distribution and activity of Na, K-ATPase in ventricular myocardium. Arch. Biochem. Biophys., 2008, 475(2), 121-127.
120. Verrey, F.; Summa, V.; Heitzmann, D.; Mordasini, D.; Vandewalle, A.; Feraille, E.; Zecevic, M., Short-term aldosterone action on Na,K-ATPase surface expression-Role of aldosteroneinduced SGK1? In Na,K-Atpase and Related Cation Pumps: Structure, Function, and Regulatory Mechanisms, New York Acad Sciences: New York, 2003; pp 554-561.
121. Otulakowski, G.; O'Brodovich, H. Thyroid hormone and Na+-K+-ATPase: more than simple transcription. Am. J. Physiol.-Lung Cell. Mol. Physiol., 2007, 292(1), L4-L5.
122. Xie, G. L.; Yan, H.; Lu, Z. F. Inhibition of glucocorticoid-induced changes of Na+, K+-ATPase in rat lens by a glucocorticoid receptor antagonist RU486. Exp. Eye Res., 2010, 91(4), 544-549.
123. Kanoh, N.; Hori, K.; Hori, S., Bidirectional regulation of strial Na-K-ATPase activity by catecholamines. In Equilibrium Research, Clinical Equilibriometry and Modern Treatment, Elsevier Science Bv: Amsterdam, 2000; pp 56-56.
124. Rosta, K.; Tulassay, E.; Enzsoly, A.; Ronai, K.; Szantho, A.; Pandics, T.; Fekete, A.; Mandl, P.; Ver, A. Insulin induced translocation of Na+/K+-ATPase is decreased in the heart of streptozotocin diabetic rats. Acta Pharmacol. Sin., 2009, 30(12), 1616-1624.
125. Vinciguerra, M.; Deschenes, G.; Hasler, U.; Mordasini, D.; Rousselot, M.; Doucet, A.; Vandewalle, A.; Martin, P. Y.; Feraille, E. Intracellular Na+ controls cell surface expression of Na,KATPase via a cAMP-independent PKA pathway in mammalian kidney collecting duct cells. Mol. Biol. Cell, 2003, 14(7), 2677-2688.
126. Blanco, G.; Nguyen, A. N.; Rodova, M. The transcription factor CREM tau and cAMP regulate the activity of the Na,K-ATPase alpha 4 isoform promoter. Faseb J., 2006, 20(5), A1238-A1238.
127. Rodova, M.; Nguyen, A. N.; Blanco, G. The transcription factor CREM tau and cAMP regulate promoter activity of the Na,KATPase alpha 4 isoform. Mol. Reprod. Dev., 2006, 73(11), 1435-1447.
128. Tian, J.; Li, X.; Liang, M.; Liu, L. J.; Xie, J. X.; Ye, Q. Q.; Kometiani, P.; Tillekeratne, M.; Jin, R. M.; Xie, Z. J. Changes in Sodium Pump Expression Dictate the Effects of Ouabain on Cell Growth. J. Biol. Chem., 2009, 284(22), 14921-14929.
129. Weigand, K. M.; Swarts, H. G. P.; Fedosova, N. U.; Russel, F. G. M.; Koenderink, J. B. Na,K-ATPase activity modulates Src activation: A role for ATP/ADP ratio. Biochim. Biophys. Acta-Biomembr., 2012, 1818(5), 1269-1273.
130. Haux, J. Digitoxin is a potential anticancer agent for several types of cancer. Med. Hypotheses, 1999, 53(6), 543-548.
131. Gentile, D. A.; Henry, J.; Katz, A. J.; Skoner, D. P. Inhibition of peripheral blood mononuclear cell proliferation by cardiac glycosides. Ann. Allergy Asthma Immunol., 1997, 78(5), 466-472.
132. Johansson, S.; Lindholm, P.; Gullbo, J.; Larsson, P.; Bohlin, L.; Claeson, P. Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anti-Cancer Drugs, 2001, 12(5), 475-483.
133. Rosenkranz, V.; Wink, M. Induction of apoptosis by alkaloids, non-protein amino acids, and cardiac glycosides in human promyelotic HL-60 cells. Z.Naturforsch.(C), 2007, 62(5-6), 458-466.
134. Serra, S.; Cheng, S.; Zavareh, R. B.; Simpson, C.; Schimmer, A.; Ezzat, S.; Asa, S. L. The response of pancreatic endocrine tumors to cardiac glycosides. Histopathology, 2008, 53, 112-112.
135. Moustafa, A. M. Y.; Khodair, A. I.; Saleh, M. A. Structural elucidation and evaluation of toxicity and antitumor activity of cardiac glycosides isolated from Leptadenia pyrotechnica. Pharm. Biol., 2009, 47(9), 826-834.
136. Zhao, Q.; Guo, Y. W.; Feng, B.; Li, L.; Huang, C. G.; Jiao, B. H. Neriifolin from seeds of Cerbera manghas L. induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. Fitoterapia, 2011, 82(5), 735-741.
137. Hundeshagen, P.; Hamacher-Brady, A.; Eils, R.; Brady, N. R. Concurrent detection of autolysosome formation and lysosomal degradation by flow cytometry in a high-content screen for inducers of autophagy. BMC Biol., 2011, 9, 1-15.
138. Xie, C. M.; Chan, W. Y.; Yu, S.; Zhao, J.; Cheng, C. H. K. Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. Free Radic. Biol. Med., 2011, 51(7), 1365-1375.
139. Wang, Y.; Qiu, Q.; Shen, J. J.; Li, D. D.; Jiang, X. J.; Si, S. Y.; Shao, R. G.; Wang, Z. Cardiac glycosides induce autophagy in human non-small cell lung cancer cells through regulation of dual signaling pathways. Int. J. Biochem. Cell Biol., 2012, 44(11), 1813-1824.
140. Tsai, S. C.; Yang, J. S.; Peng, S. F.; Lu, C. C.; Chiang, J. H.; Chung, J. G.; Lin, M. W.; Lin, J. K.; Amagaya, S.; Chung, C. W. S.; Tung, T. T.; Huang, W. W.; Tseng, M. T. Bufalin increases sensitivity to AKT/mTOR-induced autophagic cell death in SKHEP-1 human hepatocellular carcinoma cells. Int. J. Oncol., 2012, 41(4), 1431-1442.
141. Raghavendra, P. B.; Sreenivasan, Y.; Manna, S. K. Oleandrin induces apoptosis in human, but not in murine cells: Dephosphorylation of Akt, expression of FasL, and alteration of membrane fluidity. Mol. Immunol., 2007, 44(9), 2292-2302.
142. Poburko, D.; Demaurex, N. Regulation of the mitochondrial proton gradient by cytosolic Ca2+ signals. Pflugers Arch., 2012, 464(1), 19-26.
143. Lefranc, F.; Kiss, R. The sodium pump alpha(1) subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia, 2008, 10(3), 198-206.
144. Simbula, G.; Glascott, P. A.; Akita, S.; Hoek, J. B.; Farber, J. L. Two mechanisms by which ATP depletion potentiates induction of the mitochondrial permeability transition. Am. J. Physiol.-Cell Physiol., 1997, 273(2), C479-C488.
145. Rasola, A.; Bernardi, P. Mitochondrial permeability transition in Ca2+-dependent apoptosis and necrosis. Cell Calcium, 2011, 50(3), 222-233.
146. Suriyo, T.; Watcharasit, P.; Thiantanawat, A.; Satayavivad, J. Arsenite promotes apoptosis and dysfunction in microvascular endothelial cells via an alteration of intracellular calcium homeostasis. Toxicol. Vitro, 2012, 26(3), 386-395.
147. Tripathi, A.; Chaube, S. K. High cytosolic free calcium level signals apoptosis through mitochondria-caspase mediated pathway in rat eggs cultured in vitro. Apoptosis, 2012, 17(5), 439-448.
148. McConkey, D. J.; Lin, Y.; Nutt, L. K.; Ozel, H. Z.; Newman, R. A. Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res., 2000, 60(14), 3807-3812.
149. Goldman, A.; Chen, H.; Khan, M. R.; Roesly, H.; Hill, K. A.; Shahidullah, M.; Mandal, A.; Delamere, N. A.; Dvorak, K. The Na+/H+ Exchanger Controls Deoxycholic Acid-Induced Apoptosis by a H+-Activated, Na+-Dependent Ionic Shift in Esophageal Cells. PLoS One, 2011, 6(8), 1-14.
150. Che, X. F.; Zheng, C. L.; Akiyama, S. I.; Tomoda, A. 2-Aminophenoxazine-3-one and 2-amino-4,4 alpha-dihydro-4 alpha,7-dimethyl-3H-phenoxazine-3-one cause cellular apoptosis by reducing higher intracellular pH in cancer cells. Proc. Jpn. Acad. Ser. B-Phys. Biol. Sci., 2011, 87(4), 199-213.
151. Panayiotidis, M. I.; Franco, R.; Bortner, C. D.; Cidlowski, J. A. Ouabain-induced perturbations in intracellular ionic homeostasis regulate death receptor-mediated apoptosis. Apoptosis, 2010, 15(7), 834-849.
152. Winnicka, K.; Bielawski, K.; Bielawska, A.; Miltyk, W. Dual effects of ouabain, digoxin and proscillaridin A on the regulation of apoptosis in human fibroblasts. Nat. Prod. Res., 2010, 24(3), 274-285.
153. Qi, F. H.; Inagaki, Y.; Gao, B.; Cui, X. Y.; Xu, H. L.; Kokudo, N.; Li, A. Y.; Tang, W. Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas-and mitochondriamediated pathways. Cancer Sci., 2011, 102(5), 951-958.
154. Xie, X. B.; Yin, J. Q.; Wen, L. L.; Gao, Z. H.; Zou, C. Y.; Wang, J.; Huang, G.; Tang, Q. L.; Colombo, C.; He, W. L.; Jia, Q.; Shen, J. N. Critical Role of Heat Shock Protein 27 in Bufalin-Induced Apoptosis in Human Osteosarcomas: A Proteomic-Based Research. PLoS One, 2012, 7(10), 1-9.
155. Qiu, J.; Gao, H. Q.; Liang, Y.; Yu, H.; Zhou, R. H. Comparative proteomics analysis reveals role of heat shock protein 60 in digoxin-induced toxicity in human endothelial cells. BBA-Proteins Proteomics, 2008, 1784(11), 1857-1864.
156. Joly, A. L.; Wettstein, G.; Mignot, G.; Ghiringhelli, F.; Garrido, C. Dual Role of Heat Shock Proteins as Regulators of Apoptosis and Innate Immunity. J. Innate Immun., 2010, 2(3), 238-247.
157. Lanneau, D.; Brunet, M.; Frisan, E.; Solary, E.; Fontenay, M.; Garrido, C. Heat shock proteins: essential proteins for apoptosis regulation. J. Cell. Mol. Med., 2008, 12(3), 743-761.
158. Raghavendra, P. B.; Sreenivasan, Y.; Ramesh, G. T.; Manna, S. K. Cardiac glycoside induces cell death via FasL by activating calcineurin and NF-AT, but apoptosis initially proceeds through activation of caspases. Apoptosis, 2007, 12(2), 307-318.
159. Frese, S.; Frese-Schaper, M.; Andres, A. C.; Miescher, D.; Zumkehr, B.; Schmid, R. A. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res., 2006, 66(11), 5867-5874.
160. Badr, C. E.; Wurdinger, T.; Nilsson, J.; Niers, J. M.; Whalen, M.; Degterev, A.; Tannous, B. A. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway. Neuro-Oncology, 2011, 13(11), 1213-1224.
161. Yang, Q. F.; Huang, W.; Jozwik, C.; Lin, Y.; Glasman, M.; Caohuy, H.; Srivastava, M.; Esposito, D.; Gillette, W.; Hartley, J.; Pollard, H. B. Cardiac glycosides inhibit TNF-alpha/NF-kappa B signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor. Proc. Natl. Acad. Sci. USA, 2005, 102(27), 9631-9636.
162. Nguyen, K. T. D.; Buljan, V.; Else, P. L.; Pow, D. V.; Balcar, V. J. Cardiac Glycosides Ouabain and Digoxin Interfere with the Regulation of Glutamate Transporter GLAST in Astrocytes Cultured from Neonatal Rat Brain. Neurochem. Res., 2010, 35(12), 2062-2069.
163. Lopez-Lazaro, M. Digoxin, HIF-1, and cancer. Proc. Natl. Acad. Sci. USA, 2009, 106(9), E26-E26.
164. Lin, J.; Denmeade, S.; Carducci, M. A. HIF-1 alpha and Calcium Signaling as Targets for Treatment of Prostate Cancer by Cardiac Glycosides. Curr. Cancer Drug Targets, 2009, 9(7), 881-887.
165. Gayed, B. A.; O'Malley, K. J.; Pilch, J.; Wang, Z. Digoxin Inhibits Blood Vessel Density and HIF-1 alpha Expression in Castration-Resistant C4-2 Xenograft Prostate Tumors. CTS-Clin. Transl. Sci., 2012, 5(1), 39-42.
166. Zhang, H. F.; Qian, D. Z.; Tan, Y. S.; Lee, K.; Gao, P.; Ren, Y. R.; Rey, S.; Hammer, H.; Chang, D.; Pili, R.; Dang, C. V.; Liu, J. O.; Semenza, G. L. Digoxin and other cardiac glycosides inhibit HIF-1 alpha synthesis and block tumor growth. Proc. Natl. Acad. Sci. USA, 2008, 105(50), 19579-19586.
167. Prassas, I.; Paliouras, M.; Datti, A.; Diamandis, E. P. Highthroughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: Implications for cancer therapies. Clin. Cancer Res., 2008, 14(18), 5778-5784.
168. Masuda, Y.; Kawazoe, N.; Nakajo, S.; Yoshida, T.; Kuroiwa, Y.; Nakaya, K. Bufalin Induces Apoptosis and Influences the Expression of Apoptosis-Related Genes in Human Leukemia-Cells. Leuk. Res., 1995, 19(8), 549-556.
169. Huang, W. W.; Yang, J. S.; Pai, S. J.; Wu, P. P.; Chang, S. J.; Chueh, F. S.; Fan, M. J.; Chiou, S. M.; Kuo, H. M.; Yeh, C. C.; Chen, P. Y.; Tsuzuki, M.; Chung, J. G. Bufalin induces G(0)/G(1) phase arrest through inhibiting the levels of cyclin D, cyclin E, CDK2 and CDK4, and triggers apoptosis via mitochondrial signaling pathway in T24 human bladder cancer cells. Mutat. Res.-Fundam. Mol. Mech. Mutagen., 2012, 732(1-2), 26-33.
170. Jiang, Y. T.; Zhang, Y.; Luan, J. L.; Duan, H. Y.; Zhang, F.; Yagasaki, K.; Zhang, G. Y. Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action. Cytotechnology, 2010, 62(6), 573-583.
171. Zhu, Z. T.; Sun, H. Z.; Ma, G. Y.; Wang, Z. H.; Li, E. Z.; Liu, Y. Y.; Liu, Y. P. Bufalin Induces Lung Cancer Cell Apoptosis via the Inhibition of PI3K/Akt Pathway. Int. J. Mol. Sci., 2012, 13(2), 2025-2035.
172. Takai, N.; Ueda, T.; Ishii, T.; Kira, N.; Nishida, M.; Nishida, Y.; Nasu, K.; Narahara, H. Effects of Bufalin on the Proliferation of Human Choriocarcinoma Cells. Int. J. Gynecol. Cancer, 2011, 21(6), 1105-1109.
173. Yu, C. H.; Kan, S. F.; Pu, H. F.; Jea Chien, E.; Wang, P. S. Apoptotic signaling in bufalin-and cinobufagin-treated androgendependent and-independent human prostate cancer cells. Cancer Sci., 2008, 99(12), 2467-2476.
174. Takai, N.; Ueda, T.; Nishida, M.; Nasu, K.; Narahara, H. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int. J. Mol. Med., 2008, 21(5), 637-643.
175. Li, D.; Qu, X. J.; Hou, K. Z.; Zhang, Y.; Dong, Q.; Teng, Y.; Zhang, J. D.; Liu, Y. P. PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anti-Cancer Drugs, 2009, 20(1), 59-64.
176. Yin, J. Q.; Shen, J. N.; Su, W. W.; Wang, J.; Huang, G.; Jin, S.; Guo, Q. C.; Zou, C. Y.; Li, H. M.; Li, F. B. Bufalin induces apoptosis in human osteosarcoma U-2OS and U-2OS methotrexate300-resistant cell lines. Acta Pharmacol. Sin., 2007, 28(5), 712-720.
177. Hong, S. H.; Choi, Y. H. Bufalin induces apoptosis through activation of both the intrinsic and extrinsic pathways in human bladder cancer cells. Oncol. Res., 2012, 27(1), 114-120.
178. Hallbook, H.; Felth, J.; Eriksson, A.; Fryknas, M.; Bohlin, L.; Larsson, R.; Gullbo, J. Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia. PLoS One, 2011, 6(1), 1-7.
179. Perne, A.; Muellner, M. K.; Steinrueck, M.; Craig-Mueller, N.; Mayerhofer, J.; Schwarzinger, I.; Sloane, M.; Uras, I. Z.; Hoermann, G.; Nijman, S. M. B.; Mayerhofer, M. Cardiac Glycosides Induce Cell Death in Human Cells by Inhibiting General Protein Synthesis. PLoS One, 2009, 4(12), 1-9.
180. Sun, L.; Chen, T. S.; Wang, X. P.; Chen, Y.; Wei, X. B. Bufalin Induces Reactive Oxygen Species Dependent Bax Translocation and Apoptosis in ASTC-a-1 Cells. Evid.-based Complement Altern. Med., 2011, 2011, 1-12.
181. Gasper, R.; Vandenbussche, G.; Goormaghtigh, E. Ouabaininduced modifications of prostate cancer cell lipidome investigated with mass spectrometry and FTIR spectroscopy. Biochim. Biophys. Acta-Biomembr., 2011, 1808(3), 597-605.
182. Lopez-Ladzaro, M.; Pastor, N.; Azrak, S. S.; Ayuso, M. J.; Austin, C. A.; Cortes, F. Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J. Nat. Prod., 2005, 68(11), 1642-1645.
183. Winnicka, K.; Bielawski, K.; Bielawska, A.; Surazynski, A. Antiproliferative activity of derivatives of ouabain, digoxin and proscillaridin a in human MCF-7 and MDA-MB-231 breast cancer cells. Biol. Pharm. Bull., 2008, 31(6), 1131-1140.
184. Bielawski, K.; Winnicka, K.; Bielawska, A. Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol. Pharm. Bull., 2006, 29(7), 1493-1497.
185. Winnicka, K.; Bielawska, A.; Bielawski, K. Inhibition of DNA Topoisomerases I and Ii by G3 Pamam-Nh2 Dendrimer-Modified Digoxin and Proscillaridin a Conjugates in a Cell Free System. Acta Pol. Pharm., 2010, 67(6), 630-634.
186. Zavareh, R. B.; Lau, K. S.; Hurren, R.; Datti, A.; Ashline, D. J.; Gronda, M.; Cheung, P.; Simpson, C. D.; Liu, W.; Wasylishen, A. R.; Boutros, P. C.; Shi, H.; Vengopal, A.; Jurisica, I.; Penn, L. Z.; Reinhold, V. N.; Ezzat, S.; Wrana, J.; Rose, D. R.; Schachter, H.; Dennis, J. W.; Schimmer, A. D. Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. Cancer Res., 2008, 68(16), 6688-6697.
187. Xu, J. W.; Jin, R. M.; Li, E. Q.; Wang, Y. R.; Bai, Y. Signal pathways in ouabain-induced proliferation of leukemia cells. World Journal of Pediatrics 2009, 5(2), 140-145.
188. Golden, W. C.; Martin, L. J. Low-dose ouabain protects against excitotoxic apoptosis and up-regulates nuclear bcl-2 in vivo. Neuroscience, 2006, 137(1), 133-144.
189. Ahern, T. P.; Lash, T. L.; Sorensen, H. T.; Pedersen, L. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res., 2008, 10(6), 1-8.
190. Biggar, R. J.; Wohlfahrt, J.; Oudin, A.; Hjuler, T.; Melbye, M. Digoxin Use and the Risk of Breast Cancer in Women. J. Clin. Oncol., 2011, 29(16), 2165-2170.
191. Biggar, R. J. Molecular Pathways: Digoxin Use and Estrogen-Sensitive Cancers-Risks and Possible Therapeutic Implications. Clin. Cancer Res., 2012, 18(8), 2133-2137.
192. Riganti, C.; Campia, I.; Polimeni, M.; Pescarmona, G.; Ghigo, D.; Bosia, A. Digoxin and ouabain induce P-glycoprotein by activating calmodulin kinase II and hypoxia-inducible factor-1 alpha in human colon cancer cells. Toxicol. Appl. Pharmacol., 2009, 240(3), 385-392.
193. Prassas, I.; Diamandis, E. P. Novel therapeutic applications of cardiac glycosides. Nat. Rev. Drug Discov., 2008, 7(11), 926-935.
194. Lukas, D. S.; Demartin AG. Binding of digitoxin and some related cardenolides to human plasma proteins. J. Clin. Invest., 1969, 48(6), 1041.
195. Walsh, P. C. Re: A Novel Two-Stage, Transdisciplinary Study Identifies Digoxin as a Possible Drug for Prostate Cancer Treatment. J. Urol., 2012, 187(1), 143-143.
196. Patel, M.; Paulus, Y. M.; Gobin, Y. P.; Djaballah, H.; Marr, B.; Dunkel, I. J.; Brodie, S.; Antczak, C.; Folberg, R.; Abramson, D. H. Intra-arterial and Oral Digoxin Therapy for Retinoblastoma. Ophthalmic Genet., 2011, 32(3), 147-150.
197. Lopez-Lazaro, M. Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. Expert Opin. Ther. Targets, 2007, 11(8), 1043-1053.
198. Hung, Y. J.; Liu, H. E. A hearty solution for acute myeloid leukemia. Acta Pharmacol. Sin., 2012, 33(1), 1-2.
199. Pal, S. K.; Reckamp, K.; Yu, H.; Figlin, R. A. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin. Investig. Drugs, 2010, 19(11), 1355-1366.
200. Kayali, F.; Janjua, M. A.; Laber, D. A.; Miller, D. M.; Day, J. M.; Kloecker, G. H. Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol., 2009, 27(15), 9-13.
201. Taur, J. S.; DesJardins, C. S.; Schuck, E. L.; Wong, Y. N. Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells. Xenobiotica, 2011, 41(4), 320-326.
202. Dakroub, Z.; Kreydiyyeh, S. I. Sphingosine-1-phosphate is a mediator of TNF-alpha action on the Na+/K+ ATPase in HepG2 cells. J. Cell. Biochem., 2012, 113(6), 2077-2085.
203. Sopjani, M.; Alesutan, I.; Wilmes, J.; Dermaku-Sopjani, M.; Lam, R. S.; Koutsouki, E.; Jakupi, M.; Foller, M.; Lang, F. Stimulation of Na+/K+ ATPase activity and Na+ coupled glucose transport by beta-catenin. Biochem. Biophys. Res. Commun., 2010, 402(3), 467-470.
204. Freeman, A.; Hetzel, U.; Cripps, P.; Mobasheri, A. Expression of the plasma membrane markers aquaporin 1 (AQP1), glucose transporter 1 (GLUT1) and Na, K-ATPase in canine mammary glands and mammary tumours. Vet. J., 2010, 185(1), 90-93.
205. Yang, P.; Cartwright, C.; Efuet, E.; Hamilton, S. R.; Wistuba, I. I.; Menter, D.; Addington, C.; Shureiqi, I.; Newman, R. A. Cellular location and expression of Na(+), K(+)-ATPase α subunits affect the anti-proliferative activity of oleandrin. Molecular Carcinogenesis, 2012, in press, doi: 10.1002/mc.21968.
206. Li, Z. C.; Zhang, Z. B.; Xie, J. X.; Li, X.; Tian, J.; Cai, T.; Cui, H. J.; Ding, H. F.; Shapiro, J. I.; Xie, Z. J. Na/K-ATPase Mimetic pNaKtide Peptide Inhibits the Growth of Human Cancer Cells. J. Biol. Chem., 2011, 286(37), 32394-32403.
207. Yin, W.; Cheng, W.; Shen, W.; Shu, L.; Zhao, J.; Zhang, J.; Hua, Z. C. Impairment of Na+,K+-ATPase in CD95(APO-1)-induced human T-cell leukemia cell apoptosis mediated by glutathione depletion and generation of hydrogen peroxide. Leukemia, 2007, 21(8), 1669-1678.
208. Mijatovic, T.; Jungwirth, U.; Heffeter, P.; Hoda, M. A. R.; Dornetshuber, R.; Kiss, R.; Berger, W. The Na+/K+-ATPase is the Achilles Heel of multi-drug-resistant cancer cells. Cancer Lett., 2009, 282(1), 30-34.
209. Garcia, D. G.; Amorim, L. M. F.; Faria, M. V. D.; Freire, A. S.; Santelli, R. E.; Da Fonseca, C. O.; Quirico-Santos, T.; Burth, P. The anticancer drug perillyl alcohol is a Na/K-ATPase inhibitor. Mol. Cell. Biochem., 2010, 345(1-2), 29-34.
210. Arimochi, J.; Kobayashi, A.; Maeda, M. Stable expression and visualization of Mat-8 (FXYD-3) tagged with a fluorescent protein in Chinese Hamster Ovary (CHO)-K1 cells. Biotechnol. Lett., 2005, 27(14), 1017-1024.
211. Geering, K. Function of FXYD proteins, regulators of Na,KATPase. J. Bioenerg. Biomembr., 2005, 37(6), 387-392.
212. Crambert, G.; Fuzesi, M.; Garty, H.; Karlish, S.; Geering, K. Phospholemman (FXYD1) associates with Na,K-ATPase and regulates its transport properties. Proc. Natl. Acad. Sci. USA, 2002, 99(17), 11476-11481.
213. Floyd, R. V.; Wray, S.; Martin-Vasallo, P.; Mobasheri, A. Differential cellular expression of FXYD1 (phospholemman) and FXYD2 (gamma subunit of Na, K-ATPase) in normal human tissues: A study using high density human tissue microarrays. Ann. Anat.-Anat. Anz., 2010, 192(1), 7-16.
214. Bibert, S.; Roy, S.; Schaer, D.; Horisberger, J. D.; Geering, K. Phosphorylation of phospholemman (FXYD1) by protein kinases A and C modulates distinct Na,K-ATPase isozymes. J. Biol. Chem., 2008, 283(1), 476-486.
215. Teriete, P.; Thai, K.; Choi, J.; Marassi, F. M. Effects of PKA phosphorylation on the conformation of the Na,K-ATPase regulatory protein FXYD1. Biochim. Biophys. Acta-Biomembr., 2009, 1788(11), 2462-2470.
216. Song, Q. J.; Pallikkuth, S.; Bossuyt, J.; Bers, D. M.; Robia, S. L. Phosphomimetic mutations enhance FXYD1 (Phospholemman) oligomerization and reduce its interaction with the Na/K-ATPase in live cells. Circulation, 2010, 122(21).
217. Adalat, S.; Papakrivopoulou, J.; Woolf, A. S.; Bockenhauer, D. HNF1B and FXYD2 co-expression helps explain renal magnesium wasting in the renal cysts and diabetes syndrome. Pediatr. Nephrol., 2010, 25(9), 1977-1977.
218. Venteo, S.; Bourane, S.; Mechaly, I.; Sar, C.; Samad, O. A.; Puech, S.; Blostein, R.; Valmier, J.; Pattyn, A.; Carroll, P. Regulation of the Na,K-ATPase Gamma-Subunit FXYD2 by runx1 and ret signaling in normal and injured non-peptidergic nociceptive sensory neurons. PLoS One, 2012, 7(1), 1-9.
219. Wetzel, R. K.; Pascoa, J. L.; Arystarkhova, E. Stress-induced expression of the gamma subunit (FXYD2) modulates Na, KATPase activity and cell growth. J. Biol. Chem., 2004, 279(40), 41750-41757.
220. Gaut, J. P.; Crimmins, D. L.; Lockwood, C. M.; McQuillan, J. J.; Ladenson, J. H. Expression of the Na+/K+-Transporting ATPase Gamma Subunit FXYD2 in Chromophobe Renal Cell Carcinoma and Renal Oncocytoma. Lab. Invest., 2012, 92, 206A-206A.
221. Crambert, G.; Li, C. M.; Claeys, D.; Geering, K. FXYD3 (Mat-8), a new regulator of Na,K-ATPase. Mol. Biol. Cell, 2005, 16(5), 2363-2371.
222. Yamamoto, H.; Okumura, K.; Toshima, S.; Mukaisho, K.; Sugihara, H.; Hattori, T.; Kato, M.; Asano, S. FXYD3 Protein Involved in Tumor Cell Proliferation Is Overproduced in Human Breast Cancer Tissues. Biol. Pharm. Bull., 2009, 32(7), 1148-1154.
223. Morrison, B. W.; Moorman, J. R.; Kowdley, G. C.; Kobayashi, Y. M.; Jones, L. R.; Leder, P. Mat-8, a Novel Phospholemman-Like Protein Expressed in Human Breast-Tumors, Induces a Chloride Conductance in Xenopus Oocytes. J. Biol. Chem., 1995, 270(5), 2176-2182.
224. Grzmil, M.; Voigt, S.; Thelen, P.; Hemmerlein, B.; Helmke, K.; Burfeind, P. Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells. Int. J. Oncol., 2004, 24(1), 97-105.
225. Zhu, Z. L.; Zhao, Z. R.; Zhang, Y.; Yang, Y. H.; Wang, Z. M.; Cui, D. S.; Wang, M. W.; Kleeff, J.; Kayed, H.; Yan, B. Y.; Sun, X. F. Expression and significance of FXYD-3 protein in gastric adenocarcinoma. Dis. Markers, 2010, 28(2), 63-69.
226. Wang, M. W.; Gu, P.; Zhang, Z. Y.; Zhu, Z. L.; Geng, Y.; Kayed, H.; Zentgraf, H.; Sun, X. F. FXYD3 Expression in Gliomas and its Clinicopathological Significance. Oncol. Res., 2009, 18(4), 133-139.
227. Kleeff, J.; Kayed, H.; Kolb, A.; Zentgraf, H.; Buchler, M. W.; Friess, H. Fxyd3 is over-expressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. Gastroenterology, 2005, 128(4), A485-A485.
228. Loftas, P.; Onnesjo, S.; Widegren, E.; Adell, G.; Kayed, H.; Kleeff, J.; Zentgraf, H.; Sun, X. F. Expression of Fxyd-3 Is an Independent Prognostic Factor in Rectal Cancer Patients with Preoperative Radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 2009, 75(1), 137-142.
229. Widegren, E.; Onnesjo, S.; Arbman, G.; Kayed, H.; Zentgraf, H.; Kleeff, J.; Zhang, H.; Sun, X. F. Expression of FXYD3 Protein in Relation to Biological and Clinicopathological Variables in Colorectal Cancers. Chemotherapy, 2009, 55(6), 407-413.
230. Wong, J. C.; Chan, S. K.; Schaeffer, D. F.; Kennecke, H.; Jones, S. J.; Owen, D. A.; Tai, I. T. Changes in FXYD3 and NPM1 Expressions Are Early Markers of Adenomas in the Colon. Gastroenterology, 2009, 136(5), A745-A745.
231. Marín-Aguilera, M.; Mengual, L.; Burset, M.; Oliver, A.; Ars, E.; Ribal, M. J.; Colomer, D.; Mellado, B.; Villavicencio, H.; Algaba, F.; Alcaraz, A. Molecular Lymph Node Staging in Bladder Urothelial Carcinoma: Impact on Survival Eur. Urol., 2008, 54(6), 1363-1372.
232. Okudela, K.; Yazawa, T.; Ishii, J.; Woo, T.; Mitsui, H.; Bunai, T.; Sakaeda, M.; Shimoyamada, H.; Sato, H.; Tajiri, M.; Ogawa, N.; Masuda, M.; Sugimura, H.; Kitamura, H. Down-Regulation of FXYD3 Expression in Human Lung Cancers Its Mechanism and Potential Role in Carcinogenesis. Am. J. Pathol., 2009, 175(6), 2646-2656.
233. Sugimura, H. Down-Regulation of FXYD3 Expression in Human Lung Cancers: Its Mechanism and Potential Role in Carcinogenesis (vol 175, pg 2646, 2009). Am. J. Pathol., 2010, 176(5), 2581-2581.
234. Yamamoto, H.; Mukaisho, K.; Sugihara, H.; Hattori, T.; Asano, S. Down-Regulation of FXYD3 Is Induced by Transforming Growth Factor-beta Signaling via ZEB1/delta EF1 in Human Mammary Epithelial Cells. Biol. Pharm. Bull., 2011, 34(3), 324-329.
235. Bibert, S.; Aebischer, D.; Desgranges, F.; Roy, S.; Schaer, D.; Kharoubi-Hess, S.; Horisberger, J. D.; Geering, K. A Link between FXYD3 (Mat-8)-mediated Na,K-ATPase Regulation and Differentiation of Caco-2 Intestinal Epithelial Cells. Mol. Biol. Cell, 2009, 20(4), 1132-1140.
236. Garty, H.; Lindzen, M.; Fuzesi, M.; Aizman, R.; Goldshleger, R.; Asher, C.; Karlish, S. J. D., A specific functional interaction between CHIF and Na,K-ATPase-Role of FXYD proteins in the cellular regulation of the pump. In Na,K-Atpase and Related Cation Pumps: Structure, Function, and Regulatory Mechanisms, New York Acad Sciences: New York, 2003; pp 395-400.
237. Beguin, P.; Crambert, G.; Guennoun, S.; Garty, H.; Horisberger, J. D.; Geering, K. CHIF, a member of the FXYD protein family, is a regulator of Na,K-ATPase distinct from the gamma-subunit. Embo J., 2001, 20(15), 3993-4002.
238. Goldschmidt, I.; Grahammer, F.; Warth, R.; Schulz-Baldes, A.; Garty, H.; Greger, R.; Bleich, M. Kidney and colon electrolyte transport in CHIF knockout mice. Cell. Physiol. Biochem., 2004, 14(1-2), 113-120.
239. Lubarski, I.; Asher, C.; Garty, H. FXYD5 (dysadherin) regulates the paracellular permeability in cultured kidney collecting duct cells. Am. J. Physiol.-Renal Physiol., 2011, 301(6), F1270-F1280.
240. Schuler, Y.; Lee-Thedieck, C.; Geiger, K.; Kaiser, T.; Ino, Y.; Aicher, W. K.; Klein, G. Osteoblast-secreted factors enhance the expression of dysadherin and CCL2-dependent migration of renal carcinoma cells. Int. J. Cancer, 2012, 130(2), 288-299.
241. Maehata, Y.; Hirahashi, M.; Aishima, S.; Kishimoto, J.; Hirohashi, S.; Yao, T.; Takashima, H.; Tsuneyoshi, M.; Oda, Y. Significance of dysadherin and E-cadherin expression in differentiated-type gastric carcinoma with submucosal invasion. Hum. Pathol., 2011, 42(4), 558-567.
242. Giotakis, I.; Chrysovergis, A.; Georgolios, A.; Giotakis, E.; Manolopoulos, L. Adhesion molecules in cancer of the head and neck: role of dysadherin. J. Buon, 2011, 16(4), 609-612.
243. Mitselou, A.; Batistatou, A.; Nakanishi, Y.; Hirohashi, S.; Vougiouklakis, T.; Charalabopoulos, K. Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites. Histol. Histopath., 2011, 25(10), 1257-1267.
244. Batistatou, A.; Peschos, D.; Tsanou, H.; Charalabopoulos, A.; Nakanishi, Y.; Hirohashi, S.; Agnantis, N. J.; Charalabopoulos, K. In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin. Br. J. Cancer, 2007, 96(9), 1404-1408.
245. Park, J. R.; Kim, R. J.; Lee, Y. K.; Kim, S. R.; Roh, K. J.; Oh, S. H.; Kong, G.; Kang, K. S.; Nam, J. S. Dysadherin can enhance tumorigenesis by conferring properties of stem-like cells to hepatocellular carcinoma cells. J. Hepatol., 2011, 54(1), 122-131.
246. Izumi, T.; Oda, Y.; Hasegawa, T.; Nakanishi, Y.; Iwasaki, H.; Sonobe, H.; Goto, H.; Kusakabe, H.; Takahira, T.; Kobayashi, C.; Kawaguchi, K.; Saito, T.; Yamamoto, H.; Tamiya, S.; Iwamoto, Y.; Tsuneyoshi, M. Prognostic significance of dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Mod. Pathol., 2006, 19(6), 820-831.
247. Shimada, Y.; Hashimoto, Y.; Kan, T.; Kawamura, J.; Okumura, T.; Soma, T.; Kondo, K.; Teratani, N.; Watanabe, G.; Ino, Y.; Sakamoto, M.; Hirohashi, S.; Imamura, M. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. Oncology, 2004, 67(1), 73-80.
248. Lubarski, I.; Karlish, S. J. D.; Garty, H. Structural and functional interactions between FXYD5 and the Na+-K+-ATPase. Am. J. Physiol.-Renal Physiol., 2007, 293(6), F1818-F1826.
249. Miller, T. J.; Davis, P. B. S163 is critical for FXYD5 modulation of wound healing in airway epithelial cells. Wound Repair Regen., 2008, 16(6), 791-799.
250. Shindo, Y.; Morishita, K.; Kotake, E.; Miura, H.; Carninci, P.; Kawai, J.; Hayashizaki, Y.; Hino, A.; Kanda, T.; Kusakabe, Y. FXYD6, a Na,K-ATPase Regulator, Is Expressed in Type II Taste Cells. Biosci. Biotechnol. Biochem., 2011, 75(6), 1061-1066.
251. Delprat, B.; Schaert, D.; Roy, S.; Wang, J.; Puel, J. L.; Geering, K. FXYD6 is a novel regulator of Na,K-ATPase expressed in the inner ear. J. Biol. Chem., 2007, 282(10), 7450-7456.
252. Miyashita, T.; Akiyama, K.; Inamoto, R.; Matsubara, A.; Nakagawa, T.; Yamaguchi, F.; Tokuda, M.; Mori, N. Presence of FXYD6 in the endolymphatic sac epithelia. Neurosci. Lett., 2012, 513(1), 47-50.
253. Liu, J. G.; Zhou, N. X.; Zhang, X. D. A monoclonal antibody against human FXYD6. Hybridoma, 2011, 30(5), 487-490.
254. Crambert, G.; Beguin, P.; Uldry, M.; Monnet-Tschudi, F.; Horisberger, J. D.; Garty, H.; Geering, K., FXYD7, the first brainand isoform-specific regulator of Na,K-ATPase-Biosynthesis and function of its posttranslational modifications. In Na,K-Atpase and Related Cation Pumps: Structure, Function, and Regulatory Mechanisms, New York Acad Sciences: New York, 2003; pp 444-448.
255. Crambert, G.; Li, C. M.; Swee, L. K.; Geering, K. FXYD7, mapping of functional sites involved in endoplasmic reticulum export, association with and regulation of Na,K-ATPase. J. Biol. Chem., 2004, 279(29), 30888-30895.
256. Beguin, P.; Crambert, G.; Monnet-Tschudi, F.; Uldry, M.; Horisberger, J. D.; Garty, H.; Geering, K. FXYD7 is a brainspecific regulator of Na,K-ATPase alpha 1-beta isozymes. Embo J., 2002, 21(13), 3264-3273.
257. Schoner, W. Endogenous cardiotonic steroids. Cell. Mol. Biol. 2001, 47(2), 273-280.
258. Gottlieb, S. S.; Rogowski, A. C.; Weinberg, M.; Krichten, C. M.; Hamilton, B. P.; Hamlyn, J. M. Elevated Concentrations of Endogenous Ouabain in Patients with Congestive-Heart-Failure. Circulation, 1992, 86(2), 420-425.
259. Graves, S. W.; Valdes, R.; Brown, B. A.; Knight, A. B.; Craig, H. R. Endogenous Digoxin-Immunoreactive Substance in Human Pregnancies. J. Clin. Endocrinol. Metab., 1984, 58(4), 748-750.
260. Lichtstein, D.; Gati, I.; Samuelov, S.; Berson, D.; Rozenman, Y.; Landau, L.; Deutsch, J. Identification of Digitalis-Like Compounds in Human Cataractous Lenses. Eur. J. Biochem., 1993, 216(1), 261-268.
261. Lichtstein, D.; McGowan, M. H.; Russell, P.; Carper, D. A. Digitalis and digitalislike compounds down-regulate gene expression of the intracellular signaling protein 14-3-3 in rat lens. Hypertens. Res., 2000, 23, S51-S53.
262. McKinnon, W.; Lord, G. A.; Forni, L. G.; Hilton, P. J. Circulating sodium pump inhibitors in five volume-expanded humans. J. Hypertens., 2003, 21(12), 2315-2321.
263. Li, S. Q.; Eim, C.; Kirch, U.; Lang, R. E.; Schoner, W. Bovine adrenals and hypothalamus are a major source of proscillaridin Aand ouabain-immunoreactivities. Life Sci., 1998, 62(11), 1023-1033.
264. Bagrov, A. Y.; Fedorova, O. V.; Austinlane, J. L.; Dmitrieva, R. I.; Anderson, D. E. Endogenous Marinobufagenin-Like Immunoreactive Factor and Na+,K+ Atpase Inhibition during Voluntary Hypoventilation. Hypertension, 1995, 26(5), 781-788.
265. McCarty, M. F. Marinobufagenin and cyclic strain may activate endothelial NADPH oxidase, contributing to the adverse impact of salty diets on vascular and cerebral health. Med. Hypotheses, 2012, 78(2), 191-196.
266. Komiyama, Y.; Dong, X. H.; Nishimura, N.; Masaki, H.; Yoshika, M.; Masuda, M.; Takahashi, H. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure. Clin. Biochem., 2005, 38(1), 36-45.
267. Schoner, W. Ouabain, a new steroid hormone of adrenal gland and hypothalamus. Exp. Clin. Endocrinol. Diabet., 2000, 108(7), 449-454.
268. Fedorova, O. V.; Shapiro, J. I.; Bagrov, A. Y. Endogenous cardiotonic steroids and salt-sensitive hypertension. Biochim. Biophys. Acta-Mol. Basis Dis., 2010, 1802(12), 1230-1236.
269. Puschett, J. B.; Agunanne, E.; Uddin, M. N. Emerging Role of the Bufadienolides in Cardiovascular and Kidney Diseases. Am. J. Kidney Dis., 2010, 56(2), 359-370.
270. Bagrov, A. Y.; Shapiro, J. I.; Fedorova, O. V. Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets. Pharmacol. Rev. 2009, 61(1), 9-38.
271. Nesher, M.; Dvela, M.; Igbokwe, V. U.; Rosen, H.; Lichtstein, D. Physiological roles of endogenous ouabain in normal rats. Am. J. Physiol.-Heart Circul. Physiol., 2009, 297(6), H2026-H2034.
272. Schaefer, T. L.; Lingrel, J. B.; Moseley, A. E.; Vorhees, C. V.; Williams, M. T. Targeted Mutations in the Na,K-ATPase Alpha 2 Isoform Confer Ouabain Resistance and Result in Abnormal Behavior in Mice. Synapse, 2011, 65(6), 520-531.
273. Nesher, M.; Shpolansky, U.; Rosen, H.; Lichtstein, D. The digitalis-like steroid hormones: New mechanisms of action and biological significance. Life Sci., 2007, 80(23), 2093-2107.
274. Schoner, W.; Scheiner-Bobis, G. Endogenous cardiac glycosides: Hormones using the sodium pump as signal transducer. Semin. Nephrol., 2005, 25(5), 343-351.
275. Rosen, H.; Glukhman, V.; Feldmann, T.; Fridman, E.; Lichtstein, D. Cardiac steroids induce changes in recycling of the plasma membrane in human NT2 cells. Mol. Biol. Cell, 2004, 15(3), 1044-1054.
276. Correa, G. D.; Cunha, K. C. D.; dos Santos, A. A.; de Araujo, E. G. The Trophic Effect of Ouabain on Retinal Ganglion Cell is Mediated by EGF Receptor and PKC delta Activation. Neurochem. Res., 2010, 35(9), 1343-1352.
277. Dvela, M.; Rosen, H.; Ben-Ami, H. C.; Lichtstein, D. Endogenous ouabain regulates cell viability. Am. J. Physiol.-Cell Physiol., 2012, 302(2), C442-C452.
278. Cao, Y. G.; Song, Y.; An, N.; Zeng, S.; Wang, D. C.; Yu, L.; Zhu, T. F.; Zhang, T. D.; Cui, J.; Zhou, C. F.; Deng, X. M. The effects of telocinobufagin isolated from Chan Su on the activation and cytokine secretion of immunocytes in vitro. Fundam. Clin. Pharmacol., 2009, 23(4), 457-464.
279. Cunha, G. A.; Resck, I. S.; Cavalcanti, B. C.; Pessoa, C. O.; Moraes, M. O.; Ferreira, J. R. O.; Rodrigues, F. A. R.; dos Santos, M. L. Cytotoxic profile of natural and some modified bufadienolides from toad Rhinella schneideri parotoid gland secretion. Toxicon, 2010, 56(3), 339-348.
280. Valente, R. C.; Capella, L. S.; Nascimento, C. R.; Lopes, A. G.; Capella, M. A. M. Modulation of multidrug resistance protein (MRP1/ABCC1) expression: A novel physiological role for ouabain. Cell Biol. Toxicol., 2007, 23(6), 421-427.
281. Ye, M.; Qu, G. Q.; Guo, H. Z.; Guo, D. Novel cytotoxic bufadienolides derived from bufalin by microbial hydroxylation and their structure-activity relationships. J. Steroid Biochem. Mol. Biol., 2004, 91(1-2), 87-98.
282. Staroske, T.; Hennig, L.; Welzel, P.; Hofmann, H. J.; Muller, D.; Hausler, T.; Sheldrick, W. S.; Zillikens, S.; Gretzer, B.; Pusch, H.; Glitsch, H. G. Synthesis and pharmacological properties of cardenolides substituted at the butenolide part. Tetrahedron, 1996, 52(39), 12723-12744.
283. Langenhan, J. M.; Peters, N. R.; Guzei, I. A.; Hoffmann, M.; Thorson, J. S. Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization. Proc. Natl. Acad. Sci. USA, 2005, 102(35), 12305-12310.
284. Newman, R. A.; Kondo, Y.; Yokoyama, T.; Dixon, S.; Cartwright, C.; Chan, D.; Johansen, M.; Yang, P. Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. Integr. Cancer Ther., 2007, 6(4), 354-364.
285. Newman, R. A.; Yang, P. Y.; Pawlus, A. D.; Block, K. I. Cardiac glycosides as novel cancer therapeutic agents. Mol. Interv., 2008, 8(1), 36-49.
286. Juncker, T.; Cerella, C.; Teiten, M. H.; Morceau, F.; Schumacher, M.; Ghelfi, J.; Gaascht, F.; Schnekenburger, M.; Henry, E.; Dicato, M.; Diederich, M. UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells. Biochem. Pharmacol., 2011, 81(1), 13-23.
287. Mijatovic, T.; Lefranc, F.; Van Quaquebeke, E.; Van Vynckt, F.; Darro, F.; Kiss, R. UNBS1450: A new hemisynthetic cardenolide with promising anticancer activity. Mol. Cancer Ther., 2007, 6(12), 3543S-3543S.
288. Mijatovic, T.; De Neve, N.; Mathieu, V.; Van Quaquebeke, E.; Darro, F.; Kiss, R. UNBS1450-mediated c-Myc down-regulation and nucleolar targeting in carcinoma cells through over-expressed sodium pump alpha-1 subunit. Mol. Cancer Ther., 2007, 6(12), 3482S-3483S.
289. Mijatovic, T.; Lefranc, F.; Van Quaquebeke, E.; Van Vynckt, F.; Darro, F.; Kiss, R. UNBS1450: A new hemi-synthetic cardenolide with promising anti-cancer activity. Drug Dev. Res., 2007, 68(4), 164-173.
290. Lefranc, F.; Mijatovic, T.; Camby, I.; Darro, F.; Van Quaquebeke, E.; Kiss, R. The binding of the UNBS1450 cardenolide to the sodium pump in human glioblastoma (GBM) cells dramatically impairs both their migration and proliferation properties. Neuro-Oncology, 2006, 8(4), 331-331.
291. Mijatovic, T.; Op de Beeck, A.; Van Quaquebeke, E.; Dewelle, J.; Darro, F.; de Launoit, Y.; Kiss, R. The cardenolide UNBS1450 is able to deactivate nuclear factor kappa B-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol. Cancer Ther., 2006, 5(2), 391-399.
292. Juncker, T.; Schumacher, M.; Dicato, M.; Diederich, M. UNBS1450 from Calotropis procera as a regulator of signaling pathways involved in proliferation and cell death. Biochem. Pharmacol., 2009, 78(1), 1-10.
293. Jensen, M.; Schmidt, S.; Fedosova, N. U.; Mollenhauer, J.; Jensen, H. H. Synthesis and evaluation of cardiac glycoside mimics as potential anticancer drugs. Bioorg. Med. Chem., 2011, 19(7), 2407-2417.
294. Langenhan, J. M.; Engle, J. M.; Slevin, L. K.; Fay, L. R.; Lucker, R. W.; Smith, K. R.; Endo, M. M. Modifying the glycosidic linkage in digitoxin analogs provides selective cytotoxins. Bioorg. Med. Chem. Lett., 2008, 18(2), 670-673.
295. Iyer, A. K. V.; Zhou, M. Q.; Azad, N.; Elbaz, H.; Wang, L.; Rogalsky, D. K.; Rojanasakul, Y.; O'Doherty, G. A.; Langenhan, J. M. A Direct Comparison of the Anticancer Activities of Digitoxin MeON-Neoglycosides and O-Glycosides. ACS Med. Chem. Lett., 2010, 1(7), 326-330.
296. Ahmed, Z.; Deyama, Y.; Yoshimura, Y.; Suzuki, K. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B. Cancer Chemother. Pharmacol., 2009, 63(4), 643-650.
297. Felth, J.; Rickardson, L.; Rosen, J.; Wickstrom, M.; Fryknas, M.; Lindskog, M.; Bohlin, L.; Gullbo, J. Cytotoxic Effects of Cardiac Glycosides in Colon Cancer Cells, Alone and in Combination with Standard Chemotherapeutic Drugs. J. Nat. Prod., 2009, 72(11), 1969-1974.
298. Tummala, R.; Wolle, D.; Barwe, S. P.; Sampson, V. B.; Rajasekaran, A. K.; Pendyala, L. Expression of Na,K-ATPasebeta(1) subunit increases uptake and sensitizes carcinoma cells to oxaliplatin. Cancer Chemother. Pharmacol., 2009, 64(6), 1187-1194.
299. Gao, Y.; Li, H. X.; Xu, L. T.; Wang, P.; Xu, L. Y.; Cohen, L.; Yang, P. Y.; Gu, K.; Meng, Z. Q. Bufalin enhances the antiproliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. Mol. Biol. Rep., 2012, 39(2), 1683-1689.
300. Wang, L.; Raju, U.; Milas, L.; Molkentine, D.; Zhang, Z.; Yang, P. Y.; Cohen, L.; Meng, Z. Q.; Liao, Z. X. Huachansu, Containing Cardiac Glycosides, Enhances Radiosensitivity of Human Lung Cancer Cells. Anticancer Res., 2011, 31(6), 2141-2148.
301. Nasu, S.; Milas, L.; Kawabe, S.; Raju, U.; Newman, R. A. Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process. Cancer Lett., 2002, 185(2), 145-151.
302. Pastor, N.; Cortes, F. Bufalin influences the repair of X-rayinduced DNA breaks in Chinese hamster cells. DNA Repair, 2003, 2(12), 1353-1360.
303. Wang, Z.; Zheng, M.; Li, Z. C.; Li, R. G.; Jia, L. J.; Xiong, X. F.; Southall, N.; Wang, S. M.; Xia, M. H.; Austin, C. P.; Zheng, W.; Xie, Z. J.; Sun, Y. Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition. Cancer Res., 2009, 69(16), 6556-6564.
304. Prassas, I.; Karagiannis, G. S.; Batruch, I.; Dimitromanolakis, A.; Datti, A.; Diamandis, E. P. Digitoxin-Induced Cytotoxicity in Cancer Cells Is Mediated through Distinct Kinase and Interferon Signaling Networks. Mol. Cancer Ther., 2011, 10(11), 2083-2093.
305. Arimochi, J.; Ohashi-Kobayashi, A.; Maeda, M. Interaction of Mat-8 (FXYD-3) with Na+/K+-ATPase in colorectal cancer cells. Biol. Pharm. Bull., 2007, 30(4), 648-654.
306. Li, H. X.; Wang, P.; Gao, Y.; Zhu, X. Y.; Liu, L. M.; Cohen, L.; Meng, Z. Q.; Yang, P. Y. Na+/K+-ATPase alpha 3 mediates sensitivity of hepatocellular carcinoma cells to bufalin. Oncol. Res., 2012, 25(3), 825-830.
307. Stock, C.; Ludwig, F. T.; Schwab, A. Is the Multifunctional Na+/H+ Exchanger Isoform 1 a Potential Therapeutic Target in Cancer? Curr. Med. Chem., 2012, 19(5), 647-660.
308. Jing, Y. K.; Ohizumi, H.; Kawazoe, N.; Hashimoto, S.; Masuda, Y.; Nakajo, S.; Yoshida, T.; Kuroiwa, Y.; Nakaya, K. Selective Inhibitory Effect of Bufalin on Growth of Human Tumor-Cells in-Vitro-Association with the Induction of Apoptosis in Leukemia Hl-60 Cells. Jpn. J. Cancer Res., 1994, 85(6), 645-651.
309. Xu, G. X.; Wang, T. T. Apoptosis of lens epithelial cells induced by cinobufagin in vitro. Int. J. Ophthalmol., 2010, 3(2), 128-131.
310. Ihenetu, K.; Qazzaz, H. M.; Crespo, F.; Fernandez-Botran, R.; Valdes, R. Digoxin-like immunoreactive factors induce apoptosis in human acute T-cell lymphoblastic leukemia. Clin. Chem., 2007, 53(7), 1315-1322.
311. Lin, H.; Juang, J. L.; Wang, P. S. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. J. Biol. Chem., 2004, 279(28), 29302-29307.
312. Svensson, A.; Azarbayjani, F.; Backman, U.; Matsumoto, T.; Christofferson, R. Digoxin inhibits neuroblastoma tumor growth in mice. Anticancer Res., 2005, 25(1A), 207-212.
313. Wei, J. S.; Huang, H. L.; Kao, C. Y.; Liao, C. H.; Chang, K. W. Determination of digitoxin-induced elevated hydrogen peroxide levels in SK-Hep-1 cells using a chemiluminescent method. J. Food Drug Anal., 2008, 16(1), 75-79.
314. Feng, B.; Guo, Y. W.; Huang, C. G.; Li, L.; Chen, R. H.; Jiao, B. H. 2 '-epi-2 '-O-Acetylthevetin B extracted from seeds of Cerbera manghas L. induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. Chem.-Biol. Interact., 2010, 183(1), 142-153.
315. Huang, Y. T.; Chueh, S. C.; Teng, C. M.; Guh, J. H. Investigation of ouabain-induced anticancer effect in human androgenindependent prostate cancer PC-3 cells. Biochem. Pharmacol., 2004, 67(4), 727-733.
316. Yang, P. Y.; Menter, D. G.; Cartwright, C.; Chan, D.; Dixon, S.; Suraokar, M.; Mendoza, G.; Llansa, N.; Newman, R. A. Oleandrinmediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets. Mol. Cancer Ther., 2009, 8(8), 2319-2328.
317. Sreenivasan, Y.; Raghavendra, P. B.; Manna, S. K. Oleandrinmediated expression of fas potentiates apoptosis in tumor cells. J. Clin. Immunol., 2006, 26(4), 308-322.
318. Smith, J. A.; Madden, T.; Vijjeswarapu, M.; Newman, R. A. Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin. Biochem. Pharmacol., 2001, 62(4), 469-472.
319. Winnicka, K.; Bielawski, K.; Bielawska, A.; Miltyk, W. Apoptosismediated cytotoxicity of ouabain, digoxin and proscillaridin A in the estrogen independent MDA-MB-231 breast cancer cells. Arch. Pharm. Res., 2007, 30(10), 1216-1224.
320. http://clinicaltrials.gov/ct2/show/NCT00650910 Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer. (10.5.2012),
321. http://clinicaltrials.gov/ct2/show/study/NCT01162135 Digoxin for Recurrent Prostate Cancer. (10.5.2012),
322. http://clinicaltrials.gov/ct2/show/NCT00281021 Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer. (10.5.2012),
323. http://clinicaltrials.gov/ct2/show/NCT00554268 Trial of PBI-05204 in Advanced Cancer Patients. (10.5.2012),
324. http://clinicaltrials.gov/ct2/show/NCT00837239 Huachansu & Gemcitabine in Pancreatic Cancer. (10.5.2012),
325. Sunol, M.; Cusi, V.; Cruz, O.; Kiss, R.; Lefranc, F. Immunohistochemical Analyses of alpha 1 and alpha 3 Na+/K+-ATPase Subunit Expression in Medulloblastomas. Anticancer Res., 2011, 31(3), 953-958.
326. Shibuya, K.; Fukuoka, J.; Fujii, T.; Shimoda, E.; Shimizu, T.; Sakai, H.; Tsukada, K. Increase in ouabain-sensitive K+-ATPase activity in hepatocellular carcinoma by overexpression of Na+,K+-ATPase alpha 3-isoform. Eur. J. Pharmacol., 2010, 638(1-3), 42-46.
327. Rajasekaran, S. A.; Huynh, T. P.; Wolle, D. G.; Espineda, C. E.; Inge, L. J.; Skay, A.; Lassman, C.; Nicholas, S. B.; Harper, J. F.; Reeves, A. E.; Ahmed, M. M.; Leatherman, J. M.; Mullin, J. M.; Rajasekaran, A. K. Na,K-ATPase Subunits as Markers for Epithelial-Mesenchymal Transition in Cancer and Fibrosis. Mol. Cancer Ther., 2010, 9(6), 1515-1524.
328. Inge, L. J.; Rajasekaran, S. A.; Yoshimoto, K.; Mischel, P. S.; McBride, W.; Landaw, E.; Rajasekaran, A. K. Evidence for a potential tumor suppressor role for the Na,K-ATPase beta(1)-subunit. Histol. Histopath., 2008, 23(4), 459-467.
329. Espineda, C.; Seligson, D. B.; Ball, W. J.; Rao, J. Y.; Palotie, A.; Horvath, S.; Huang, Y.; Shi, T.; Rajasekaran, A. K. Analysis of the Na,K-ATPase alpha-and beta-subunit expression profiles of bladder cancer using tissue microarrays. Cancer, 2003, 97(8), 1859-1868.
330. Rajasekaran, S. A.; Ball, W. J.; Bander, N. H.; Liu, H.; Pardee, J. D.; Rajasekaran, A. K. Reduced expression of beta-subunit of Na,K-ATPase in human clear-cell renal cell carcinoma. J. Urol., 1999, 162(2), 574-580.